The market for Inflammatory Bowel Disease (IBD) is expected to experience substantial growth from 2020 to 2034, as detailed in the latest report titled “Inflammatory Bowel Disease Market Insights, Epidemiology and Market Forecast, 2034” from DelveInsight. This growth is driven by a rise in IBD cases across various regions, which increases the demand for advanced diagnostic and treatment options.
Factors contributing to this surge include a higher disease burden, significant advances in understanding disease mechanisms, and the development of new diagnostic and therapeutic agents. Additionally, improved awareness among physicians, better diagnostic technologies, enhanced healthcare access, and increased patient and physician awareness are also boosting diagnosis rates.
The report provides comprehensive insights into current treatment practices for IBD, emerging drugs in the pipeline, market shares of individual therapies, and the projected market trajectory from 2020 to 2034 across the 7MM (the United States, EU-4 countries—Italy, Spain, France, and Germany—the United Kingdom, and Japan).
Key highlights from the Inflammatory Bowel Disease Market Report:
-
In 2023, the United States held the largest market share for inflammatory bowel disease (IBD) among the 7MM. The most commonly prescribed treatments for IBD include ASA anti-inflammatory drugs, anti-TNF agents, IL antagonists, JAK inhibitors, TLR 9 agonists, and integrins.
-
The US was responsible for approximately 50% of the total diagnosed prevalent cases of IBD in the 7MM in 2023, with an anticipated increase in cases during the forecast period from 2024 to 2034. Crohn’s disease, although less common than ulcerative colitis, is generally more severe and is most frequently diagnosed in individuals between the ages of 20 and 30.
-
In May 2024, Johnson & Johnson announced that it had submitted applications to the European Medicines Agency (EMA) to expand the Marketing Authorization Application for TREMFYA (guselkumab) to include treatment for adult patients with moderately to severely active ulcerative colitis and Crohn’s disease.
-
Additionally, in October 2023, the US FDA approved OMVOH (mirikizumab-mrkz), the first and only interleukin-23p19 antagonist, for the treatment of moderately to severely active ulcerative colitis in adults.
Driving Forces Behind the Inflammatory Bowel Disease Market Growth
The increasing prevalence of Inflammatory Bowel Disease (IBD) across various regions has led to a greater demand for advanced diagnostic tools and treatment options, driving market expansion. Several factors contribute to rising diagnosis rates, including the growing burden of IBD, substantial progress in understanding its underlying mechanisms, and the development of new diagnostic and therapeutic solutions.
Discover the Anticipated Evolution and Growth of the Market @ Inflammatory Bowel Disease Therapeutics Market Forecast
Therapeutic Advancements and Emerging Treatments:
-
Inflammatory Bowel Disease Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2034. Pioneering companies, including Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill Biopharma, Pfizer, and others, are actively engaged in developing novel drugs for potential market entry.
-
Inflammatory Bowel Disease Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Inflammatory Bowel Disease. Therapies such as Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104, Xeljanz, and others are driving the Inflammatory Bowel Disease market.
Inflammatory Bowel Disease Market Dynamics
Inflammatory Bowel Disease (IBD) currently has no cure, and treatment focuses on alleviating symptoms, preventing complications and flare-ups, and promoting the healing of inflamed intestines. Management strategies for IBD involve a combination of medications, surgical interventions, and lifestyle modifications.
The primary goal of treatment is to stop abnormal inflammation to allow intestinal tissue to heal, which typically relieves symptoms such as diarrhea and abdominal pain. Once symptoms are under control, the focus shifts to reducing flare-ups and maintaining remission. Physicians often start with the least invasive treatments and gradually escalate to more advanced options if necessary.
Currently available medications for IBD include Entyvio (Vedolizumab), a gut-selective biologic from Takeda Pharmaceutical, and Stelara (Ustekinumab) by Janssen Pharmaceuticals, which is approved for adults with moderately to severely active Crohn’s disease and Ulcerative Colitis.
Emerging therapies include Etrolizumab (RG7413), a humanized IgG1 monoclonal antibody targeting the beta-7 integrin subunit, developed by Roche and Genentech. Etrolizumab is undergoing extensive trials with over 3,100 patients across six Phase III studies. Another promising drug is Risankizumab (ABBV-066), an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim for various inflammatory diseases, including Crohn’s disease and Ulcerative Colitis. New therapies such as Skyrizi, Etrolizumab, Jyselica, and others are expected to enter the IBD treatment market during the forecast period.
Learn how the inflammatory bowel disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market
Inflammatory Bowel Disease Treatment Market
The Inflammatory Bowel Disease (IBD) treatment market encompasses pharmaceuticals, therapies, and medical interventions designed to manage and alleviate symptoms of Crohn’s disease and Ulcerative Colitis, the two main forms of IBD. This market includes a range of treatments such as anti-inflammatory drugs, immunosuppressants, biologics, steroids, and, in severe cases, surgical interventions.
As research advances and new insights into IBD emerge, the treatment market continues to evolve with the development of innovative drugs and therapies. Pharmaceutical companies are actively investing in these new treatments to address unmet needs, improve patient outcomes, and enhance quality of life.
The growth of the IBD treatment market is driven by several factors, including the rising global prevalence of the disease, technological advancements, ongoing clinical trials, and a shift towards personalized medicine. The market is highly competitive, with companies focused on creating more effective, targeted therapies to manage symptoms, achieve remission, and prevent progression. Additionally, factors such as patient education, healthcare access, and treatment affordability play crucial roles in shaping the market dynamics.
Leading Inflammatory Bowel Disease Companies and Emerging Drugs: Leading companies such as Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill Biopharma, and Pfizer are actively working on innovative drugs for potential introduction into the Inflammatory Bowel Disease market.
Inflammatory Bowel Disease Therapeutic Landscape: Notable therapies for the treatment of Inflammatory Bowel Disease include Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104, Xeljanz, and others.
Inflammatory Bowel Disease Overview:
Inflammatory Bowel Disease (IBD) is a chronic and complex condition caused by immune system dysregulation, influenced by genetic, epigenetic, microbial, and environmental factors. The two primary forms of IBD are Ulcerative Colitis (UC) and Crohn’s Disease (CD), both of which can lead to severe, debilitating symptoms and significant disruptions to daily life.
UC is characterized by the immune system attacking the lining of the intestines, causing chronic inflammation and ulcerations. There is a pressing need for new treatments that effectively alleviate symptoms such as bowel urgency and provide sustained clinical remission.
Crohn’s Disease is a chronic, immune-mediated condition that primarily affects the end of the small intestine (ileum) and the beginning of the colon, though it can involve any part of the gastrointestinal tract from mouth to anus.
Together, UC and CD impact approximately 10 million people globally.
Key Facts Inflammatory Bowel Disease Market Report:
-
Among the 7MM, the United States holds the largest market size for inflammatory bowel disease. The introduction of new therapies, such as obefazimod, MORF-057, and tulisokibart, is anticipated to drive positive market growth.
-
The limited treatment options for patients with relapsed or refractory ulcerative colitis present significant opportunities in this therapeutic area.
-
Factors such as rising prevalence, enhanced diagnostic capabilities, an aging population, advancements in treatment options, increased healthcare spending, growing awareness, and the expansion of healthcare services are expected to contribute to market growth during the forecast period from 2024 to 2034.
Inflammatory Bowel Disease Epidemiology Insights:
-
In 2023, the United States represented approximately 50% of the total diagnosed cases of Inflammatory Bowel Disease (IBD), including both Crohn’s Disease (CD) and Ulcerative Colitis (UC), across the 7MM. The number of cases in the US is expected to rise during the forecast period.
-
Within the US, moderate to severe cases of IBD were more prevalent than mild cases in 2023. The 18-44 age group had the highest number of IBD cases in the US.
-
Among the EU4 countries and the UK, Germany reported the highest prevalence of IBD cases, followed by the UK in 2023.
The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
• Total Prevalence of Inflammatory Bowel Disease
• Prevalent Cases of Inflammatory Bowel Disease by severity
• Gender-specific Prevalence of Inflammatory Bowel Disease
• Diagnosed Cases oF Inflammatory Bowel Disease
DelveInsight’s comprehensive report provides a thorough exploration of the Inflammatory Bowel Disease market, covering key Inflammatory Bowel Disease players, emerging Inflammatory Bowel Disease therapies, treatment dynamics, and market challenges.
For in-depth insights, access the full report @ Inflammatory Bowel Disease Market Outlook 2034
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/